SPRO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Spero Therapeutics Inc (SPRO) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock lacks positive catalysts, has weak financial performance, insider selling trends, and no strong trading signals. Additionally, the technical indicators and options data do not support a strong bullish case.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 50.071, suggesting no clear overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading near its pivot point of 2.471, with limited upside potential based on resistance levels (R1: 2.654, R2: 2.768). Historical trends suggest a 70% chance of a slight decline in the next day (-2.81%) and week (-2.83%).
NULL identified. No recent news or significant positive events.
Insiders are selling heavily, with a 312.04% increase in selling over the last month. Financial performance is weak, with significant YoY declines in revenue (-59.60%), net income (-56.95%), and EPS (-59.38%). No recent congress trading data or influential figure activity.
In Q3 2025, revenue dropped to $5.44M (-59.60% YoY), net income fell to -$7.38M (-56.95% YoY), and EPS declined to -0.13 (-59.38% YoY). Gross margin remained stable at 100%, but the overall financial performance indicates significant challenges.
No recent analyst ratings or price target changes are available for SPRO.
